Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1053/j.gastro.2018.06.080 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Oral Capsule FMT Combined With Bezlotoxumab Is a Successful Rescue Protocol Following Failure of FMT Alone in the Treatment of Recurrent C. difficile Infection.
J Clin Gastroenterol
November 2024
Division of Gastroenterology, Department of Medicine, University of Minnesota, Minneapolis, MN.
Article Synopsis
- The study aimed to assess the effectiveness of adding bezlotoxumab to repeat fecal microbiota transplantation (FMT) for patients with recurrent Clostridioides difficile infections after a previous unsuccessful FMT.
- It was found that combining bezlotoxumab with a second FMT significantly increased the cure rate from 48% to 89%.
- The research highlights the importance of understanding how bezlotoxumab and FMT work together and suggests that similar strategies could apply to other treatments for preventing C. difficile infection recurrence.
Objective: One of the main problems with Clostridioides difficile infection (CDI) is its tendency to recur. The objective of the study is to analyze which factors in the clinical management of CDI favor recurrence.
Methods: This is a retrospective study conducted at the Hospital Universitario Príncipe de Asturias on cases of CDI between January 2021 and June 2023.
Microbiota restoration for recurrent Clostridioides difficile infection.
Panminerva Med
December 2024
Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA -
Article Synopsis
- * Testing for CDI remains complicated due to the high sensitivity of PCR, leading to false positives, and the limited sensitivity of toxin assays, complicating accurate diagnosis.
- * Treatment prefers fidaxomicin for recurrent CDI due to its lower disruption of the microbiota compared to broad-spectrum antibiotics like vancomycin, while new FDA-approved therapies and fecal microbiota transplantation (FMT) show promise in managing this infection.
Recurrent Clostridioides difficile infections in solid organ transplant recipients: The international CALIPSO study.
J Infect
December 2024
Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy. Electronic address:
Article Synopsis
- The study aimed to assess the likelihood of recurrent Clostridioides difficile infection (CDI) in solid-organ transplant (SOT) recipients during the year following their transplant.
- Researchers analyzed data from 191 SOT patients who had their first CDI episode, finding a 12% recurrence rate and highlighting that severe CDI and metronidazole monotherapy significantly raised this risk.
- The findings suggest that using metronidazole alone increases the chances of a recurrence, indicating a need for improved treatment strategies to prevent repeated infections in these patients.
Therapeutics involved in managing initial and recurrent infection: An updated literature review.
World J Gastrointest Pharmacol Ther
September 2024
Department of Internal Medicine, Hackensack Palisades Medical Center, North Bergen, NJ 07047, United States.
Article Synopsis
- The increasing incidence of Clostridioides difficile infection (CDI) is largely due to recurrent hospitalizations and the impact of antibiotics on the gut microbiome.
- Current treatment options are limited to three main antibiotics, but rising drug resistance and recurrent infections pose significant challenges, especially among vulnerable populations like the elderly and immunocompromised.
- New treatments, including monoclonal antibodies like bezlotoxumab and fecal microbiota transplants, are being researched to better manage and prevent CDI, alongside an overview of challenges faced in treating this infection.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!